论文部分内容阅读
目的：比较海舒必（舒巴坦钠／头孢哌酮钠）与头孢噻肟钠治疗下呼吸道感染的疗效。方法：选取我院同期住院治疗的下呼吸道感染病例７０例，随机分成两组，分别给予海舒必与头孢噻肟钠治疗，均为４ｇ／ｄ，静滴，疗程７～１４ｄ。结果：海舒必组与头孢噻肟钠组的临床总有效率分别为８２．８％和６０．７％，细菌清除率分别为９６．５％和６０．５％，两者有显著性差异。结论：在治疗中度下呼吸道感染时，海舒必疗效优于其他第三代头孢菌素。
OBJECTIVE: To compare the efficacy of the combination of sulbactam (sodium sulbactam / cefoperazone sodium) and cefotaxime sodium in the treatment of lower respiratory tract infections. Methods: Seventy patients with lower respiratory tract infection hospitalized in our hospital at the same period were randomly divided into two groups. All patients were treated with 4% sodium dithranone and cefotaxime sodium, intravenous infusion for 7-14 days. Results: The total effective rates of the two groups were 82.8% and 60.7% respectively, and the bacterial clearance rate was 96.5% and 60.5%, respectively, with significant difference between the two groups . Conclusion: In the treatment of moderate lower respiratory tract infection, the effect of Haishuibe is better than that of other third generation cephalosporins.